Morria Biopharmaceuticals Inc. Announces Publication Of The Results Of Its Human Pilot Study In Contact Dermatitis Patients Of MRX1, A Novel First-in-Class MFAID

LONDON--(BUSINESS WIRE)--Morria Biopharmaceuticals Plc, a biopharmaceutical company focusing on novel, non-steroidal anti-inflammatory drugs, announced today the publication of results from its human pilot clinical trial on its leading topical Multi-Functional Anti Inflammatory Drug (MFAID) MRX1. The results of the study are published in the upcoming edition of the International Journal of Immunopathology and Pharmacology. MRX1 was tested in a double-blind placebo controlled study on 11 contact dermatitis patients at the Hadassah University Hospital in Israel. The pilot clinical study findings show that a topical preparation of MRX1, applied twice daily for 14 days, scored 69% improvement based on conventional Physician’s Assessment versus a standard 30% placebo effect generated by the moisturizing vehicle.
MORE ON THIS TOPIC